Edition:
United States

Avita Medical Ltd (AVH.AX)

AVH.AX on Australia Stock Exchange

0.07AUD
18 Aug 2017
Change (% chg)

$0.00 (+1.43%)
Prev Close
$0.07
Open
$0.07
Day's High
$0.07
Day's Low
$0.07
Volume
660,182
Avg. Vol
536,065
52-wk High
$0.14
52-wk Low
$0.07

Latest Key Developments (Source: Significant Developments)

Avita Medical appoints Michael S Perry as CEO
Thursday, 1 Jun 2017 07:11pm EDT 

June 2 (Reuters) - Avita Medical Ltd :Avita Medical appoints Michael S Perry as CEO.  Full Article

Avita Medical says FDA approves more compassionate use cases & sites for ReCell
Thursday, 6 Apr 2017 07:41pm EDT 

Avita Medical Ltd : Asx alert-FDA approves more compassionate use cases & sites for recell-AVH.AX . U.S. FDA approved further increase in number of patients who can be treated in U.S. With recell regenerative medical device under Avita Medical .Expects to submit its clinical and non-clinical data package in mid-2017, with an anticipated FDA approval in the second calendar quarter of 2018.  Full Article

Avita signs distributor deal in Iran
Wednesday, 28 Sep 2016 08:48pm EDT 

Avita Medical Ltd :Avita signs exclusive distributor deal in Iran.  Full Article

Avita Medical says co signs a deal for distribution in Malaysia
Monday, 6 Jun 2016 08:05pm EDT 

Avita Medical Ltd : Avita Medical signs deal for distribution in malaysia Full Article

Avita Medical signs distributor deal with china's healthcare group
Thursday, 10 Mar 2016 06:50pm EST 

Avita Medical Ltd:Signs Distributor Deal With China's Largest Healthcare Group.Sinopharm, China's largest healthcare group, is granted sole distribution of the Avita range.Sales and Distribution across China to be run by the group's MedTech subsidiary.Says the deal, signed in Beijing on Thursday with Sinopharm's MedTech subsidiary, grants exclusive distribution of the Avita range of medical devices.  Full Article

Avita Medical Ltd announces FDA approval for increase in Compassionate use of ReCell Patient Cases
Monday, 7 Mar 2016 06:00am EST 

Avita Medical Ltd:Says approval from the U.S. Food and Drug Administration (FDA) for a second expansion of its Compassionate Use Investigational Device Exemption (IDE) program for ReCell.  Full Article

Avita Medical launches expanded regenerative product range in Europe
Wednesday, 2 Mar 2016 02:19pm EST 

Avita Medical:Says Avita Medical launches expanded regenerative product range in Europe.  Full Article

Avita Medical Ltd updates on divestment of respiratory business
Thursday, 4 Feb 2016 11:53pm EST 

Avita Medical Ltd:Divestment of respiratory business.Says has completed the sale of its respiratory business to Medical Developments International Limited for $2.47 mln.Says sale represents the second input of non-dilutive capital Avita has received in recent months.Already invoicing barda under a program to support the completion of avita's FDA approval and its entry to the US market".  Full Article

Avita Medical sells respiratory business for $2.64m to Medical Developments International
Thursday, 24 Dec 2015 06:00am EST 

Avita Medical Ltd:Announced that it has signed an agreement to sell its respiratory business to Medical Developments International for $2.64m.  Full Article

Avita Medical Ltd Receives Australian Patent
Wednesday, 18 Nov 2015 09:25am EST 

Avita Medical Ltd:Received a new Australian patent which effectively extends the original ReCell patents to 2033 in Australia and provides greater claim coverage.Patent No. AU2013202587 relates to use of the Company's cell suspension preparation device, ReCell®, a simple, rapid and cost-effective technique for grafting cells.  Full Article

BRIEF-Avita Medical appoints Michael S Perry as CEO

* Avita Medical appoints Michael S Perry as CEO Source text for Eikon: Further company coverage: